Abstract: The present invention relates to covalently cross-linked glycosylated mucin nanoparticles and the use thereof for the delivery and release of active ingredients, markers and/or biomolecules. The subject matter of the invention also relates to covalently cross-linked glycosylated mucin nanoparticles comprising at least one compound selected from an active ingredient, a marker and a biomolecule. The invention further relates to a method for preparing covalently cross-linked glycosylated mucin nanoparticles, optionally comprising at least one compound selected from an active ingredient, a marker and a biomolecule.

Abstract: The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.

Abstract: A three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures is provided. The three-dimensional substrate includes a diffusion system having a first apical compartment placed above a second basolateral compartment, the first and second compartments being separated by a semipermeable membrane, a base solution comprising polysaccharides, proteins and salts or a preformed hydrogel comprising polysaccharides, proteins and salts, and a cross-linking medium comprising salts, culture media and distilled water. A method for preparing a three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures is also provided.

Abstract: The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.

Abstract: Monoclonal and polyclonal antibodies are provided which can bind to the FbsA protein of Streptococcus agalactiae (GBS) and which can be used to prevent adherence of the bacteria to host cells and thus be useful in the treatment and protection against infection from S. agalactiae. The antibodies of the invention can also be raised against the fibrinogen binding domain of FbsA or the repeat region therein, and in addition to preventing bacterial adherence, the antibodies to FbsA are advantageous in that they can be used to prevent platelet aggregation and thrombus formation.

Abstract: Cross-reactive monoclonal antibodies are provided which are generated from peptides from Enterococcus faecalis, including the ACE40 and the ACE19 protein, and the CNA19 peptide from Staphylococcus aureus, and which can bind to the collagen-binding proteins from bacteria from a variety of species including enterococcal bacteria, staphylococcal bacteria and streptococcal bacteria. These monoclonal antibodies may then be formed into suitable pharmaceutical compositions, and they are thus particularly effective in providing methods of treating or preventing bacterial infections from a wide range of bacterial species.